“…Therefore, requirements for new ectoparasitic drugs should include not only the control of ectoparasites for a certain period of time, but also address their ability to block the transmission of the various vector-borne pathogens by a rapid onset of action. In this scope, "speed of kill" has become an important commercial differentiator for recent marketed products Wengenmayer et al, 2014;Beugnet et al, 2016;Blair et al, 2016; and many studies have been designed for testing the ability of those products to block transmission of some important pathogens of cats like Bartonella henselae (Bradbury and Lappin, 2010), and of dogs like Dipilidium caninum (Fourie et al, 2013a), Leishmania infantum (Brianti et al, 2014), Ehrlichia canis (Jongejan et al, 2015), Borrelia burgdorferi, Anaplasma phagocytophilum (Honsberger et al, 2016), and Babesia canis Taenzler et al, 2016). These studies all report a complete prevention of pathogen transmission by fast elimination of the vector.…”